Lam, W. K. Jacky http://orcid.org/0000-0001-8922-5609
Jiang, Peiyong
Chan, K. C. Allen
Peng, Wenlei
Shang, Huimin
Heung, Macy M. S.
Cheng, Suk Hang
Zhang, Haiqiang
Tse, O. Y. Olivia
Raghupathy, Radha
Ma, Brigette B. Y.
Hui, Edwin P.
Chan, Anthony T. C.
Woo, John K. S.
Chiu, Rossa W. K.
Lo, Y. M. Dennis http://orcid.org/0000-0001-8746-0293
Funding for this research was provided by:
Chinese University of Hong Kong (VCF2014021)
- Research Grants Council of the Hong Kong SAR Government under the Theme-based Research Scheme
Article History
Received: 24 August 2018
Accepted: 2 July 2019
First Online: 22 July 2019
Competing interests
: Y.M.D.L. is a scientific cofounder and a member of the scientific advisory board for Grail. Y.M.D.L., R.W.K.C. and K.C.A.C. hold equity in Grail and Take2 Health, and receive research funding from Grail/Cirina. Y.M.D.L., R.W.K.C. and K.C.A.C. are cofounders and board members of DRA Company Limited. P.J. is a consultant to Grail and holds equity in Grail and is nominated as a director of KingMed Future. W.K.J.L. is a consultant to Grail and holds equity in Grail. E.P.H. receives fees for serving on an advisory board for Bristol-Myers Squibb and Merck Sharp & Dohme. Y.M.D.L., R.W.K.C., K.C.A.C., P.J. and W.K.J.L. have filed patent applications based on this work.